Abstract

Human immunodeficiency virus continued to present a formidable global health challenge despite advances in 
antiretroviral therapy. Broadly neutralizing antibodies represent a unique class of immunoglobulins capable of 
recognizing conserved epitopes across diverse HIV strains, offering potential for both prevention and therapeutic 
intervention. These antibodies target critical viral envelope structures including the CD4 binding site, membrane 
proximal external region, V1V2 apex, and V3 glycan supersite, achieving viral neutralization through interference 
with host cell entry mechanisms. This review aimed to critically evaluate the biochemical properties, mechanisms of 
action, clinical efficacy, and translational challenges associated with broadly neutralizing antibodies in HIV 
prevention and treatment applications. A comprehensive synthesis of peer reviewed literature examining broadly 
neutralizing antibody discovery, structural biology, preclinical studies, clinical trials, and implementation barriers 
was conducted. Broadly neutralizing antibodies demonstrated potent in vitro neutralization of diverse HIV isolates 
and provide protection against viral acquisition in animal models. Clinical trials revealed promising 
pharmacokinetics with extended half-lives, modest virological suppression when used as monotherapy, and 
synergistic potential when combined with antiretroviral agents. Passive immunization studies indicated protective 
efficacy for prevention, though viral escape through envelope sequence variation remains problematic. Antibody 
engineering approaches including Fc modification and bispecific formats enhance potency and breadth. However, 
challenges persist regarding high production costs, need for intravenous or subcutaneous administration, resistance 
development, and limited accessibility in resource constrained settings. Broadly neutralizing antibodies constituted 
a valuable addition to HIV prevention and treatment strategies, though substantial barriers to widespread 
implementation require resolution through continued technological innovation and health system adaptations.